Cellectis and AstraZeneca Forge Strategic Collaboration and Investment Deals

Cellectis has announced a strategic collaboration and investment agreements with AstraZeneca. The collaboration aims to develop up to 10 novel cell and gene therapy candidate products in areas of high unmet need, such as oncology, immunology, and rare diseases. AstraZeneca will leverage Cellectis' gene editing technologies and manufacturing capabilities. Cellectis will receive up to $245 million in cash, including an upfront payment of $25 million, potential milestone payments, and tiered royalties. AstraZeneca will also make an initial equity investment of $80 million and potentially an additional investment of $140 million.